Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,639.30 | 1.50 | 0.02% |
| CAC 40 | 7,779.72 | 8.38 | -0.11% |
| DAX 40 | 23,933.23 | 104.96 | -0.44% |
| Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
| FTSE 100 | 8,716.45 | 9.56 | -0.11% |
| HKSE | 23,220.87 | 352.51 | -1.50% |
| NASDAQ | 19,175.87 | 74.93 | 0.39% |
| Nikkei 225 | 37,917.38 | 515.60 | -1.34% |
| NZX 50 Index | 12,378.17 | 96.86 | 0.79% |
| S&P 500 | 5,912.17 | 23.62 | 0.40% |
| S&P/ASX 200 | 8,413.90 | 4.10 | 0.05% |
| SSE Composite Index | 3,344.72 | 18.72 | -0.56% |